Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors

Institut Paoli-Calmettes274 enrolled

Overview

Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month. The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response. This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

274

Conditions

Pancreatic Tumor

Interventions

suspected pancreatic tumorPROCEDURE

Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Suspicion of pancreatic adenocarcinoma * Patient \> 18 years old * Social Security affiliation * Signed informed consent Exclusion Criteria: * Patient in emergency situation * Major person being the object of a legal protective measure or unable to express its consent

Locations (1)

Marine GILABERT, MD

Marseille, France

Outcomes

Primary Outcomes

Biomarkers

Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers

Time frame: within twenty four hours

Secondary Outcomes

Histology

To determine the histologic characteristics of the pancreatic tumor

Time frame: within twenty four hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.